Searched for
CIPLA OPTIONS
India among Asia-Pacific's most AI-ready healthcare markets as demand for coordinated care rises: BainIndia is emerging as one of the most AI-ready healthcare markets in the Asia-Pacific region, with a growing number of consumers using gener...- Cipla appoints health chief Shivam Puri to lead One India businessCipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Adani Enterprises, Cipla among 5 stocks with short buildupIn Thursday's trading session, five stocks saw fresh short positions being built
- Cipla ups investment in point-of-care testing firm Achira LabsCipla has announced further investment of up to Rs 26 crore in Achira Labs, a company specializing in point-of-care medical test kits. This...
- Cipla Options Radar: Deploy debit spread to participate in the bull runCipla's volatile journey from a 52-week high to a support level. Using Debit Spread strategy, Madhu Bansal advises on call options. Exit by...
- 2 stocks suggesting bearish trend with increase in total OI & decrease in stock price>> For more such web stories click on the ET icon below
- Cipla promoters to sell 2.5%Yusuf Hamied and Mustafa Hamied, promoters of Cipla, are selling as much as a 2.5% stake in the drugmaker through a block deal on Tuesday t...
- Cipla weighs legal options after Delhi HC's patent rulingDrug major Cipla is exploring all legal options in the wake of Delhi High Court's ruling that it has infringed Swiss drug major Hoffman-La ...
- Cipla rallies nearly 3% on getting US patent for stemcell productAt 09:40 a.m.; Cipla was trading 2.4 per cent higher at Rs 742.20. It hit a low of Rs 725 and a high of Rs 744.90 in trade today.
- Recommend to hold Cipla: Mayuresh JoshiFrom a valuation perspective specifically from an FY16 perspective our belief is Cipla around 24.5 times-25 times forward earnings seems to...
- Sun Pharma, Cipla already been re-rated a lot: P Phani SekharThey have already been re-rated a lot so I guess there is little scope at least in the longer term perspective for that to happen
- Cipla launches biosimilar for rheumatic disorders in IndiaDrug major Cipla said it has launched biosimilar of Etanercept under the brand name 'Etacept' used for treatment of rheumatic disorders in ...
- Cipla Medpro shareholder wants Cipla India to hike offer: ReportCipla Medpro is a South African affiliate of Cipla. The companies enjoy a long-standing business relationship spanning two decades.
- Cipla launches four in one drug for HIV patientsIndia’s second largest drug company Cipla has launched Qvir, a combination of four HIV drugs in one single strip.
- Cipla launches HIV/AIDS treatment kit at Rs 158Drug major Cipla today said it has launched 'Qvir', a four-drug kit priced at Rs 158 per kit to be used for treating HIV/AIDS.
- Cipla losses appeal in US court for animal healthcare productDrug firm Cipla today said it has lost an appeal in a US court over a patent case against Merial Ltd regarding an animal healthcare product.
- Adcock's plan to buy Medpro hits Cipla hurdleSouth African company Adcock Ingram's plans to buy Cipla Medpro, with whom Cipla has a 20-year drug-supply agreement, has run into trouble ...
- PEs to bankroll Cipla's Merck bidIndian drug major Cipla and private equity (PE) funds are working out an innovative financing model to bid for Merck’s generic business.
- Cipla may join PE cos in bid for Merck unitDrug major Cipla is exploring the option of joining a consortium of private equity firms in bidding for the generics business of German dru...
Load More
